Physician profile

William J Littman

Internal Medicine · Lebanon, TN

NPI 1750389607

$5,652.55

in general payments reported to CMS, 2019-2025

36 companies · $1,051 in 2025

The $1,051 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).

See the full distribution for Internal Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,979.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $792.56 2019-2025 Airsupra, Farxiga, Breztri
Amgen INC. $650.23 2019-2025 Otezla, Repatha, Repatha
Novo Nordisk INC $613.87 2019-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $555.84 2019-2025 Zepbound, Mounjaro, Jardiance
Glaxosmithkline, LLC. $322.04 2019-2024 Trelegy Ellipta
Abbvie INC. $292.40 2023-2025
Amarin Pharma, INC. $277.08 2019-2022
Novartis Pharmaceuticals Corporation $260.48 2019-2025
Bayer Healthcare Pharmaceuticals INC. $234.59 2022-2023
Boehringer Ingelheim Pharmaceuticals, INC. $197.69 2019-2025 Jardiance
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $176.00 2022-2025 Xifaxan, Trulance
Sumitomo Pharma America, INC. $154.94 2023-2025 Gemtesa
Kyowa Kirin, INC. $125.00 2023 Crysvita
Valeritas, INC. $115.49 2019
Corcept Therapeutics $96.07 2019-2024 Korlym
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $89.29 2019-2022
Regeneron Healthcare Solutions, INC. $88.90 2019
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $64.17 2025 Caplyta
Otsuka America Pharmaceutical, INC. $57.23 2024-2025 Rexulti
Exact Sciences Corporation $49.66 2023-2024 Cologuard Collection Kit
Merck Sharp & Dohme LLC $48.96 2019
Baxter Healthcare $47.76 2024 Hillrom - Carnation Ambulatory Monitor
Sanofi-Aventis U.S. LLC $38.36 2019
Esperion Therapeutics, INC. $34.20 2025 Nexletol
Insulet Corporation $33.66 2021-2022
Pfizer INC. $30.79 2022-2023
Janssen Pharmaceuticals, INC $29.22 2019-2020
Otsuka Pharmaceutical Development & Commercialization, INC. $24.66 2025
Zealand Pharma US, INC. $23.62 2021
Aimmune Therapeutics, INC. $21.74 2024
Inspire Medical Systems, INC. $21.18 2025 Inspire
Shield Therapeutics INC $21.08 2023 Accrufer
Astellas Pharma US INC $17.64 2023 Veozah
Mannkind Corporation $16.74 2024
Boston Scientific Corporation $15.74 2025 Watchman Access System
Ascensia Diabetes Care US INC. $13.67 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William J Littman

$5,652.55

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $1,051 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/215623/william-j-littman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.